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Abstract
Background: Human exposures to inorganic arsenic (iAs) have been linked to an increased risk of diabetes
mellitus. Recent laboratory studies showed that methylated trivalent metabolites of iAs may play key roles in the
diabetogenic effects of iAs. Our study examined associations between chronic exposure to iAs in drinking water,
metabolism of iAs, and prevalence of diabetes in arsenicosis-endemic areas of Mexico.
Methods: We used fasting blood glucose (FBG), fasting plasma insulin (FPI), oral glucose tolerance test (OGTT),
glycated hemoglobin (HbA1c), and insulin resistance (HOMA-IR) to characterize diabetic individuals. Arsenic levels
in drinking water and urine were determined to estimate exposure to iAs. Urinary concentrations of iAs and its
trivalent and pentavalent methylated metabolites were measured to assess iAs metabolism. Associations between
diabetes and iAs exposure or urinary metabolites of iAs were estimated by logistic regression with adjustment for
age, sex, hypertension and obesity.
Results: The prevalence of diabetes was positively associated with iAs in drinking water (OR 1.13 per 10 ppb, p <
0.01) and with the concentration of dimethylarsinite (DMAsIII) in urine (OR 1.24 per inter-quartile range, p = 0.05).
Notably, FPI and HOMA-IR were negatively associated with iAs exposure (b -2.08 and -1.64, respectively, p < 0.01),
suggesting that the mechanisms of iAs-induced diabetes differ from those underlying type-2 diabetes, which is
typically characterized by insulin resistance.
Conclusions: Our study confirms a previously reported, but frequently questioned, association between exposure
to iAs and diabetes, and is the first to link the risk of diabetes to the production of one of the most toxic
metabolites of iAs, DMAsIII.
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Background
Results of several epidemiologic studies have suggested
that chronic environmental or occupational exposures to
inorganic arsenic (iAs) increase risk of diabetes. These
studies, as well as, other studies examining the diabeto-
genic effects of iAs exposure were recently reviewed by
Navas-Acien and coworkers [1]. The association between
iAs exposure and diabetes has been frequently ques-
tioned because of methodological problems associated
with some of these studies and because these studies
focused mainly on populations exposed to high levels of
iAs [1]. In addition, results of studies examining effects of
low exposures to iAs did not support this association or
yielded conflicting results [1]. For example, a recent
study utilizing data collected by the National Health and
Nutrition Examination Survey found a significant asso-
ciation between urinary arsenic and diabetes in the
general U.S. population [2]. Another U.S. study found
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significant associations between cumulative exposure to
iAs and risk of depression or high blood pressure, but
not diabetes [3]. Conflicting information has also been
provided by studies that examined the diabetogenic
effects of iAs in laboratory animals. These studies were
recently reviewed [1,4]. In contrast, research using ex
vivo or tissue culture models has consistently shown that
exposures to subtoxic concentrations of trivalent iAs or
trivalent methylated arsenicals produce effects consistent
with diabetes, including inhibition of insulin production
by pancreatic b-cells and inhibition of basal or insulin-
stimulated glucose uptake by skeletal muscle, cultured
adipocytes, or kidney cells [4]. The tissue culture studies
have also provided clues about molecular mechanisms of
the diabetogenic effects of iAs exposure and have high-
lighted the role of specific metabolites of iAs in these
mechanisms.
The pathway for iAs metabolism in humans involves
the reduction of AsV-species to AsIII-species followed by
oxidative methylation of AsIII-species, yielding mono-
and dimethylated metabolites that contain either AsIII or
AsV [5]. Arsenic (+3 oxidation state) methyltransferase
(AS3MT) is the key enzyme in this pathway [5,6]. The
trivalent iAs, arsenite (iAsIII), and its methylated meta-
bolites containing trivalent As, methylarsonite (MAsIII)
and dimethylarsinite (DMAsIII), are generally more toxic
and reactive than their pentavalent counterparts,
arsenate (iAsV), methylarsonate (MAsV) and dimethylar-
sinate (DMAsV) [7]. These trivalent arsenicals are also
potent inhibitors of insulin-stimulated glucose uptake by
cultured murine adipocytes [8,9]. Notably, MAsIII and
DMAsIII are more potent than iAsIII as inhibitors of key
steps in the insulin-activated signal transduction path-
way, specifically, the insulin-dependent phosphorylation
of protein kinase-B (PKB) or PKB-mediated transloca-
tion of the insulin-sensitive glucose transporter, GLUT4,
from cytoplasm to the plasma membrane of adipocytes.
MAsIII, and particularly DMAsIII is unstable in human
urine [10,11] Therefore, analysis of these metabolites
requires a special sample handling and optimized analy-
tical techniques. Indeed, both MAsIII and DMAsIII were
detected in urines collected from individuals exposed to
iAs in drinking water and from acute promyelocytic leu-
kemia patients undergoing arsenic trioxide treatment
[12-17]. It has been hypothesized that because of their
exceptional toxicities, MAsIII and DMAsIII contribute to
the adverse effects of iAs exposure. Results of numerous
laboratory studies support this hypothesis [18-20]. How-
ever, to date only one study examined association
between the production of MAsIII and DMAsIII and the
adverse effects of iAs exposure in humans. This study
by Valenzuela and associates showed that carriers
of AS3MT/287Thr polymorph who have higher
concentrations of MAsIII in urine could be more suscep-
tible to adverse effects of iAs exposure than carriers of
wild-type AS3MT (AS3MT/287Met) [21].
The main goals of our study were (i) to reexamine the
link between chronic exposure to iAs and diabetes,
using multiple diabetes and exposure indicators, and (ii)
to characterize the role of iAs metabolism, including
MAsIII and DMAsIII production, in development of dia-
betes by individuals exposed to iAs in drinking water.
Results of our work show that risk of diabetes signifi-
cantly increases with iAs exposure and that urinary
DMAsIII is positively associated with this risk.
Methods
Study Subjects and Sample Collection
Study subjects were recruited among residents of the
Zimapán and Lagunera regions (Mexico), using informa-
tion on current and historical levels of iAs in local
drinking water supplies [22-26]. Potential participants
who gave written informed consent were invited for an
interview during which they completed a detailed ques-
tionnaire focusing on residence in the study areas, use
and sources of drinking water, history of disease, and
potential occupational exposures to As. The subjects
with a minimum of two-year residency in the Zimapán
or Lagunera regions and without occupational exposures
to As were recruited for the study. Pregnant women,
alcoholics, and individuals with chronic or acute dis-
eases of the urinary tract or with type I diabetes were
excluded from this study. In order to facilitate future
analyses of the genotype-phenotype associations, we
recruited only genetically unrelated individuals. All pro-
cedures included in this study were approved by Institu-
tional Review Boards of Cinvestav-IPN, Mexico City,
Mexico and University of North Carolina at Chapel Hill,
North Carolina, USA.
All subjects were examined by an experienced physi-
cian and body weight, height, blood pressure, body mass
index (BMI), and waist-to-hip ratio were recorded. A
spot urine sample was collected from each subject dur-
ing the medical exam. The urines were aliquoted and
snap-frozen in dry ice immediately after collection. Each
subject also provided a sample of water he or she had
typically used for drinking. For diagnosis of diabetes, a
sample of fasting blood was collected into EDTA-vacu-
tainers (Becton, Dickinson and Co., Franklin Lakes, NJ),
followed by oral glucose tolerance test (OGTT). Here,
each subject drank a glass of water (~200 mL) contain-
ing 75 g of anhydrous glucose (Mallinckrodt Baker, Inc.,
Xalostoc Mexico). A sample of venous blood was col-
lected two hours after glucose administration. Plasma
was prepared from both fasting and two-hour blood
samples and stored at -80°C.
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Analyses of As in Urine and Drinking Water
Only six samples of urine were collected in one day to
facilitate quantitative analysis of the unstable MAsIII and
DMAsIII. Samples collected in Zimapán were packed in
dry ice and transported by car to Cinvestav-IPN in Mex-
ico City (a two-three hour drive from Zimapán). In the
Lagunera region, urines were collected in Universidad
Juárez del Estado de Durango (UJED) and analyzed in a
local laboratory. The analysis of trivalent arsenicals,
including MAsIII and DMAsIII, was completed within 6
hours after collection. Our tests show that on average
only about 9% of DMAsIII in urine oxidizes under these
conditions (Figure 1). Pentavalent arsenicals were ana-
lyzed later in aliquots of urine that were stored at -80°C.
The metabolites of iAs in urines were analyzed by
hydride generation (HG)-atomic absorption spectrome-
try (AAS) with cryotrapping (CT). This method has
been optimized to detect all tri- and pentavalent meta-
bolites of iAs except dimethylthioarsinic acid [27,28].
Laboratory in Cinvestav-IPN used a traditional HG-CT-
AAS system with a conventional quartz tube atomizer
[28]; a more advanced HG-CT-AAS system equipped
with multiatomizer was used in UJED. Calibration
curves (0.5, 1, 2, 3, and 4 ng As/mL) were prepared
using tri- and pentavalent As standards as previously
described [28]. The Urine Arsenic reference materials
(Laboratoire de Toxicologie, INSPQ, Québec, Canada)
that contain 25.1 (S0907), 67.0 (S0902), and 202.5 ng
As/mL (S0906) were used for quality control. The con-
centrations of As species in urine were expressed as ng
As/mL or as μg As/mg creatinine. The concentrations
of creatinine were measured by Jaffe reaction (Randox
Laboratories Ltd., San Diego, CA). To control for possi-
ble differences in precision between the two analytical
laboratories, a set of eighteen urines collected in Zima-
pán and analyzed in Cinvestav-IPN were re-analyzed in
UJED. A nearly perfect correlation (R = 0.997, p < 0.01)
was found for the 2 sets of results, specifically for the
sums of As species detected in the urines (Figure 2).
The concentrations of iAs in drinking water and con-
centrations of total As (tAs) in urines were determined by
HG-atomic fluorescence spectrometry (HG-AFS) as pre-
viously described [27,29]. The Trace Elements in Water
standard reference material (SRM 1643e, National Insti-
tute of Standards and Technology, Gaithersburg, MD)
containing 60.4 ± 0.7 ng As/mL was used for quality con-
trol. The concentration of iAs in water were expressed as
ng As/mL or ppb; tAs concentration in urine were
expressed as ng As/mL or as μg As/mg creatinine.
Analyses in Blood and Plasma
1. Glucose concentrations were determined in the fast-
ing and 2-hour blood by HemoCue Glucose 201RT
glucometer (HemoCue, Lake Forest, CA) that reports
results in plasma glucose equivalents.
2. Concentration of glycated hemoglobin HbA1c was
measured in fasting blood, using a GDX A1c test car-
tridges (Cholestech Corp., Hayward, CA).
3. Insulin concentration was determined in fasting
blood plasma using the Human Insulin ELISA Kit
(Linco Research, Inc., St. Charles, MO).
Evaluation of iAs Exposure and Metabolism
The following indicators were used to estimate indivi-
dual exposure to iAs in drinking water:
1. The concentration of iAs in drinking water samples
provided by study subjects.
2. The concentration of tAs in spot urines collected
during medical exams.
3. Cumulative exposure estimated from measurements
of current and historical concentrations of iAs in drink-
ing water supplies in Zimapán and Lagunera and infor-
mation from the questionnaires about each subject’s
length of residence in these areas [22,25,26]. The mea-
surements of iAs concentration were used to estimate
the average annual exposure at each location in the study
area during the years 1993 to 2008. When a location had
no measurements in a given year, the concentration of
iAs was assumed to have remained constant since the
last year for which data was available. Cumulative expo-
sure in ppm.years was estimated for each subject by sum-
ming the annual exposures over the years during which
the subject had lived in the study area. Cumulative expo-
sure could not be estimated for the period before 1993
because only scattered measurements for a few locations
were available from 1978 to 1992 and no data were avail-
able for 1977 and before. Estimates of cumulative expo-
sures were therefore generated for the 1993-2008 period
and, to examine temporal effects, for the 5-year segments
1993-1997, 1998-2002 and 2003-2007.
The metabolic patterns for iAs were characterized by
the concentration or relative amount (% of tAs) of each
of the tri- and pentavalent metabolites of iAs in urine
and by the ratios of DMAs/MAs, MAs/iAs, and (DMAs
+MAs)/iAs.
Classification of Diabetes Status
Diabetic individuals were identified by fasting blood glu-
cose level (FBG) ≥126 mg/dL, by the two-hour blood glu-
cose level (2HBG) ≥200 mg/dL determined by OGTT,
and by self-reported doctor diagnosis of diabetes or use
of anti-diabetic medication as indicated in the question-
naires. Individuals who reported previous diagnoses of
diabetes or taking diabetes medication were not adminis-
tered OGTT. Classification by 2HBG and FBG gave
nearly identical results, so in the text we report results
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Figure 1 Effect of the storage time and temperature on DMAsIII oxidation in human urine. Spot urines from two subjects were spiked
with iododimethylarsine (DMAsIIII) at final concentrations of 15 ppb As (a) or 100 ppb As (b). DMAsIII contents were determined in urines
immediately after spiking (Control) and after 6 and 24 hours after spiking in urines stored either on ice (0°C) or in dry ice (-78°C). Mean ± SD are
shown for n = 3.
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for both indicators combined. Results for separate ana-
lyses based on FBG and 2HBG are given in Additional
Material. Fasting plasma insulin (FPI) and homeostasis
model assessment - insulin resistance (HOMA-IR = FPI
[μU/mL] × FBG [mmol/L]/22.5) were used to character-
ize insulin production and insulin resistance.
Statistical Analysis
Standard descriptive analyses were carried out using
means and standard deviations for continuous variables
and frequencies for categorical variables. The distribu-
tions of continuous variables were examined graphically
using histograms and normal probability plots. Measure-
ments of iAs in water and most biological indicators,
including iAs and its metabolites in urine were approxi-
mately log-normally distributed and for these we report
the geometric mean and standard deviation. Measured
values of MAsIII and DMAsIII that were below the limit
of detection (LOD) were replaced with LOD/21/2 for sta-
tistical analysis. The LOD for both metabolites was 0.1
ng/mL As. Associations of diabetes status with iAs and
urinary metabolites of iAs were examined using logistic
regression to estimate odds ratios (ORs) and 95% confi-
dence intervals (CIs). iAs concentration in drinking
water and concentrations of tAs and iAs metabolites in
urine were examined both as continuous variables and
in categorical form. To control for potential confound-
ing, year of age, sex, hypertension (systolic blood pres-
sure ≥140, diastolic blood pressure ≥90 or reported use
of anti-hypertensive drugs) and obesity (BMI > 30) were
included as covariates. Although the effects of adjust-
ment were negligible (< 10% change in the OR), all cov-
ariates were retained in the models because of their
known association with diabetes. Associations of
continuous variables for 2HBG, FBG, FPI, and HOMA-
IR with measures of tAs and iAs metabolites were ana-
lyzed by linear regression, with log-transformation of
tAs in water and of tAs and iAs metabolites in urine.
Age, sex, hypertension and obesity, classified as
described above, were included as covariates in these
models. The assumption of linear exposure-response
was assessed graphically and by fitting alternative mod-
els with flexible spline functions and was found to be
adequate. Because of the different concentration ranges
of urinary metabolites, we report ORs, regression coeffi-
cients, and CIs for those indicators for a one interquar-
tile range (IQR) increment of exposure to facilitate
comparison. Analyses of urinary metabolites of iAs were
conducted both with and without urinary creatinine
concentration as a covariate to assess possible effects of
variation in urine volume. Statistical adjustment for
creatinine concentrations changed the numerical values
of some regression coefficients, but the interpretation
and statistical significance of the findings remained the
same. Statistical analyses reported here were performed
in Stata/MP version 11.2 for Mac OS × (StataCorp,
College Station, TX).
Results
Characteristics of the Study Population and Exposure
to iAs
We recruited a total of 258 subjects, including 147 Zimapán
and 111 Lagunera residents, both females (109 and 65,
respectively) and males, five years old or older. Seventy-
three subjects were 18 years old or younger. Sixty subjects
were fifty years old or older. One hundred and nine subjects
reported using only tap (municipal) water or water from
private wells for both drinking and cooking. Twenty sub-
jects drank both tap and bottled water, but used only tap
water for cooking. Twenty subjects drank only bottled
water, but used the tap or well water for cooking. Ninety
one subjects, mostly from Zimapán, used only bottled
water for both drinking and cooking. One subject used only
water from a local spring. Basic characteristics of the study
population are provided in Table 1.
The concentrations of iAs in samples of drinking water
ranged from 3 to 215 ppb (ng As/mL) (Table 2). The con-
centrations of tAs in urine ranged from 2 to 234 ng As/mL
(5 to 1,512 ng As/mg creatinine). The levels of tAs deter-
mined in the chemically digested urines correlated strongly
with the sum of tri- and pentavalent metabolites of iAs
determined by HG-CT-AAS (R = 0.98; p < 0.01). Sum of
iAs metabolites in urine represented 95.2 ± 12.2% (mean ±
SD) of tAs. These data suggest that iAs metabolites
accounted for most of As in urines and that urines did not
contain significant amounts of thioarsenicals or complex
organic As species that cannot be detected by HG-CT-
AAS. We found a statistically significant correlation
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Figure 2 Correlation between sums of As species in urines of
eighteen Zimapán residents analyzed in both Cinvestav-IPN
and in Universidad Juárez del Estado de Durango (UJED): R =
0.997, p < 0.01).
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between the levels of iAs in drinking water and tAs in
urine (R = 0.27; p < 0.01) (Additional file 1). This correla-
tion was stronger for the logarithmically transformed levels
of iAs and tAs, both before and after normalization for
creatinine: R = 0.42 (p < 0.01) and R = 0.36 (p < 0.01),
respectively (Figure 3).
Urinary Metabolites of iAs
Most of the urine samples contained both tri- and penta-
valent metabolites of iAs, including iAsIII, iAsV, MAsIII,
MAsV, DMAsIII, and DMAsV (Table 2). TMAsO was not
detected. MAsIII was detected in 67% of urines collected
in Zimapán and 100% of urines collected in Lagunera;
DMAsIII was detected in 75% and 100% of urines col-
lected in Zimapán and Lagunera, respectively. In these
urines, MAsIII represented 0.1% to 18% (median 0.9%)
and DMAsIII 0.2% to 81% (median 8.6%) of tAs. We
found no statistically significant associations between the
concentration or percentage of DMAsIII or MAsIII in
urine and either age or gender of the study subjects.
However, the young (≤18-year old) subjects had a lower
average DMAs/MAs ratio (4.7) than either subjects older
than 18 years (5.9, p < 0.01) or subjects older than 50
years (6.1, p < 0.01). We also found statistically signifi-
cant positive correlations (p < 0.01) between DMAs/MAs
ratio and iAs exposure represented by either iAs concen-
tration in drinking water or tAs concentration in urine.
In contrast, the MAs/iAs ratio was negatively associated
with iAs concentration in drinking water (R = -0.19, p <
0.01) and tAs concentration in urine (R = -0.22, p < 0.01).
Associations of Diabetes with iAs Exposure and
Metabolism
Distribution of FBG, 2HBG, and HbA1c values among
study subjects is shown in Table 1. As expected, we
found strong positive correlations (R ≥ 0.78; p < 0.01)
between these three diabetes indicators. All subjects
with FBG ≥126 mg/dL or 2HBG ≥200 mg/dL were
thirty years old or older. Similarly, abnormally high
Table 1 Descriptive characteristics of the study
population
Diabetic Non-diabetic
Mean
(N)
SD
(%)
Mean
(N)
SD
(%)
Population (N, %) (25) (9.7) (233) (90.3)
Female (N, %) (19) (76.0) (155) (66.5)
Age (years) 50.4 13.1 32.3 18.0
iAs concentration in drinking water
(ppb)
77.3 61.8 39.2 44.9
Water consumption (L/day) 2.1 1.0 1.9 0.9
Bottled water for drinking (N, %) (12) (48.0) (132) (56.7)
BMI > 30 (N, %) (11) (44.0) (77) (33.1)
Hypertensive (N, %) (9) (36.0) (88) (37.8)
FBG (mg/dL) 177.4 77.5 83.8 16.0
2HBG (mg/dL) 258.4 130.0 97.3 27.4
HbA1c (%) 9.0 2.6 6.1 0.6
FPI 7.8 6.4 9.0 6.3
HOMA-IR 3.1 2.3 1.8 1.3
Table 2 Descriptive statistics for exposure to iAs in
drinking water and iAs metabolites in urine
Exposure to iAs in Water Na Range AM GM GSD
iAs, current concentration (ppb) 258 3.1 215.2 42.9 24.4 2.9
iAs, cumulative exposure 1993-2008
(ppm.years)
255 0.0 6.73 1.8 1.3 2.3
iAs, cumulative exposure 1993-1997
(ppm.years)
255 0.0 5.8 0.7 0.5 2.8
iAs, cumulative exposure 1998-2002
(ppm.years)
255 0.0 4.5 0.6 0.5 2.3
iAs, cumulative exposure 2002-2007
(ppm.years)
255 0.0 1.2 0.5 0.4 2.1
Metabolites of iAs in Urine (ng/mL)
tAs 256 2.3 233.7 41.2 24.7 2.8
iAsIII 257 0.1 37.2 4.2 2.1 3.4
MAsIII 257 ND 2.4 0.4 0.1 2.3
DMAsIII 257 ND 64.8 4.7 0.9 3.2
iAsV 257 ND 32.9 1.4 1.5 4.7
MAsV 257 0.1 36.2 5.0 1.1 1.1
DMAsV 257 0.1 162.6 22.5 2.4 1.3
DMAs/MAs ratio 257 0.4 26.4 5.6 4.8 1.7
MAs/iAs ratio 257 0.0 5.1 1.3 1.1 2.0
Abbreviations: AM, arithmetic mean; GM, geometric mean; GSD, geometric
standard deviation; ND, not detected.
a All 258 subjects provided sample of drinking water for iAs analysis; urine
samples were collected from 257 subjects and analyzed for As species; only
256 urine samples were analyzed for tAs; cumulative exposure was calculated
for 255 subjects.
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Figure 3 Correlations between logarithmically transformed
concentrations of iAs in drinking water and tAs in urines
collected from subjects in Zimapán and Lagunera: ● tAs in ng/
mL (full line); ○ tAs in μg/mg of creatinine (dashed line).
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HbA1c levels (> 7%) were found almost exclusively in
subjects thirty five years old or older. Diabetes classified
by the combination of FBG, 2HBG and reported diagno-
sis or medication was positively associated with the con-
centration of iAs in drinking water (Table 3 and
Additional files 2 and 3), with the OR increasing 13%
per 10 ppb of iAs (95% CI 1.05-1.22, p < 0.01) for the
combined classification (OR 1.15, 95% CI 1.06-1.24, p <
0.01 for classification by FBG, OR 1.14, 95% CI 1.06-
1.24, p < 0.01 for classification by 2HBG). Diabetes was
positively associated with cumulative exposure to iAs
during most recent five-year window but the OR was
imprecise, and there was no association with overall
cumulative exposure in the 1993-2008 period or with
exposure in earlier five-year windows (Table 3).
Diabetes was not notably associated with tAs or with
most of the metabolites of iAs in urine (Table 3). How-
ever, a marginally significant association (OR 1.24, 95%
CI 1.00-1.55, p = 0.05) was found with the urinary con-
centration of DMAsIII. The association of diabetes with
urinary DMAsIII was statistically significant (p = 0.04)
when diabetes was classified only by 2HBG≥200 and
reported diagnosis or medication, but and on the bor-
derline of significance (p = 0.05) when FBG≥126 mg/dL
was used (Additional file 4). The OR for diabetes
increased slightly after controlling for creatinine (OR
1.37 per IQR 95% CI 1.10-1.72, p = 0.01, data not
shown).
HbA1c level in blood was positively associated with iAs
in drinking water (p = 0.03) but unrelated to iAs or its
metabolites in urine (Table 4). FPI and HOMA-IR, which
characterize insulin production and resistance, respec-
tively, were negatively associated with the levels of iAs in
drinking water (p < 0.01) and with the concentrations of
tAs, iAsIII and DMAsIII in urine (p ≤ 0.01) (Table 4). FPI
was also negatively associated with urinary MAsIII (p =
0.02).
Discussion
The arsenicosis-endemic areas of Zimapán and Lagunera
were chosen for this study because tens of thousands of
local residents are currently exposed to a wide range of
iAs concentrations in drinking water and because rela-
tively detailed information exists about historical levels of
iAs in the local drinking water supplies. Unlike most pre-
vious studies, we used multiple biomarkers to classify dia-
betes and to characterize exposure to iAs. In spite of a
relatively small number of subjects recruited for this study
we were able to show that the exposure to iAs was posi-
tively associated with all three diabetes indicators. Our
findings contradict results of a recent study that found no
significant association of iAs exposure with diabetes in
another arsenicosis area located in Bangladesh [30]. This
study used only glycated hemoglobin (HbA1c) and gluco-
suria to classify diabetic individuals. Although the HbA1c
level in blood is now an accepted measure for diagnosis of
diabetes in the US, it is unclear whether it was also vali-
dated for the Bangladeshi population. Glucosuria is not a
reliable indicator of diabetes [31]. Thus, using the vali-
dated diabetes indicators may be essential for linking iAs
exposure to risk of diabetes. Notably, our data on the
negative associations between iAs exposure and FPI and
HOMA-IR suggest that the mechanisms of iAs-induced
diabetes differ from those underlying type-2 diabetes,
which is typically characterized by insulin resistance (i.e.,
increased HOMA-IR) and hyperinsulinemia [32].
In our study, FPG and 2HBG were significantly asso-
ciated with iAs concentration in drinking water, but not
with tAs or sum of iAs metabolites in urine. Samples of
water provided for iAs analysis represented the types and
sources of drinking water that were used by study subjects
on a daily basis for an extensive period of time. Thus, it is
plausible that iAs concentrations in these samples are
more representative of the current exposures to iAs than
are tAs levels in spot urines, which could be affected by
changes in drinking water sources or consumption during
days or even hours before urine collection. Our results
show that diabetes was not associated with cumulative
exposure to iAs over the last fifteen years. Historical
records show that levels of iAs in drinking water supplies
Table 3 Association of diabetesa with exposure to iAs in
drinking water and iAs metabolites in urine, adjusted for
age, sex, obesity and hypertension
Exposure to iAs in Water ORb 95% CI pc
iAs, current concentration 1.13 1.05 1.22 < 0.01
iAs, cumulative exposure 1993-2008 1.03 0.77 1.39 0.83
iAs, cumulative exposure, 2003-2007 3.57 0.90 14.19 0.07
iAs, cumulative exposure, 1998-2002 0.98 0.41 2.37 0.97
iAs, cumulative exposure, 1993-1997 0.88 0.52 1.48 0.61
Metabolites of iAs in Urine
tAs 1.12 0.78 1.62 0.54
iAsIII 0.94 0.61 1.46 0.79
MAsIII 1.24 0.60 2.54 0.35
DMAsIII 1.24 1.00 1.55 0.05
iAsV 1.06 0.94 1.18 0.35
MAsV 0.92 0.58 1.43 0.70
DMAsV 0.97 0.66 1.46 0.87
DMAs/MAs ratio 1.38 0.90 2.13 0.13
MAs/iAs ratio 1.02 0.92 1.13 0.72
Abbreviations: OR, odds ratio; CI, confidence interval.
a Diabetes classified by either fasting blood glucose ≥126 mg/dL, 2-hour
blood glucose ≥200 mg/dL, self-report of doctor diagnosis or use of anti-
diabetic medication.
b Units of OR and CI are 10 ppb for iAs concentration and ppm.years for
cumulative iAs exposure. ORs for iAs metabolites are standardized to an
increment of one inter-quartile range.
c p-value for comparison of cases to individuals free of diabetes.
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in both Zimapán and Lagunera areas have changed in
recent years as a result of interventions by local govern-
ments. These changes may explain the low correlation
between estimated cumulative exposure and the current
concentrations of iAs in drinking water. In addition, the
use of bottled water for drinking and cooking has become
common, particularly in Zimapán, which historically had
the higher levels of iAs in the municipal water supplies.
Previous epidemiologic studies used MAs/iAs and
DMAs/MAs ratios in urine to evaluate the efficiency of
iAs methylation and detoxification by subjects exposed
to environmental iAs. Some of these studies reported a
negative association between iAs exposure and the
DMAs/MAs ratio or %DMA in urine, suggesting satura-
tion or inhibition of the methylation pathway for iAs at
high exposure levels [33]. Other reports have linked low
DMAs/MAs ratio (or high MAs/DMAs ratio) and high
%MAs (or low %DMAs) to an increased susceptibility to
diseases associated with iAs exposure, including skin
lesions [34-36]. However, our data suggest that with
increasing iAs exposure the efficiency of iAs methylation
increases as indicated by higher DMAs/MAs and lower
MAs/iAs ratios in urine.
An important goal of the present study was to examine
associations between the prevalence of diabetes and urin-
ary concentrations of MAsIII and DMAsIII. All urine sam-
ples collected in Lagunera and analyzed in UJED by the
advanced HG-CT-AAS system contained both MAsIII
and DMAsIII. The failure to detect DMAsIII and, particu-
larly MAsIII in a large number of urines from Zimapán
was likely due to a lower sensitivity of the conventional
HG-CT-AAS system used in Cinvestav-IPN. Notably,
DMAsIII in urine was associated positively with FBG and
2HBG but negatively with FPI. These results suggest that
individuals with high concentrations of DMAsIII in urine
are at increased risk of developing diabetes. DMAsIII is a
potent inhibitor of insulin-stimulated glucose uptake by
adipocytes [8]. DMAsIII also inhibits glucose-stimulated
insulin secretion by isolated murine pancreatic islets (Sty-
blo and Douillet, unpublished data). Thus, the mechan-
ism of the diabetogenic effects of iAs exposure may
involve inhibition by DMAsIII of insulin-dependent glu-
cose uptake and metabolism in peripheral tissues and/or
inhibition by DMAsIII of insulin production by pancreatic
b-cells. Taken together these two mechanisms would
produce fasting hyperglycemia and impaired glucose tol-
erance, as well as decreased FPI and HOMA-IR values,
i.e., symptoms that are consistent with results of our
study.
While this study had notable strengths, the interpreta-
tion of the results may be affected by several limitations.
The study population was predominantly female because
men in the area often emigrate to work. Although we
adjusted for sex in the analysis, the ability to extend the
findings to populations with a more balanced sex ratio
may be limited to the extent that women and men may
differ in susceptibility to As-related disease. As noted
above, iAs exposures in the study area have changed in
recent years as a result of modifications to municipal
water systems and the use of bottled water. The negative
correlation between current and cumulative exposures
suggests that areas with historically high iAs levels were
targeted for interventions to reduce exposure. Our data
(not shown) suggest that individuals who had been told by
a doctor that they had diabetes were not more likely to
use bottled water, however. The recent changes in
Table 4 Association of log-transformed HbA1c, FPI and HOMA-IR with log-transformed concentrations of iAs in
drinking water and of iAs metabolites in urine, adjusted for age, sex, obesity and hypertension
HbA1c FPI HOMA-IR
ba 95% CI pb ba 95% CI pb ba 95% CI pb
Water iAs 0.193 0.018 0.369 0.03 -2.084 -2.720 -1.448 < 0.01 -1.641 -2.358 -0.924 < 0.01
Urinary tAs 0.164 -0.570 0.898 0.66 -5.313 -8.068 -2.559 < 0.01 -4.538 -7.514 -1.562 < 0.01
Urinary iAsIII -0.003 -0.075 0.069 0.94 -0.534 -0.803 -0.266 < 0.01 -0.409 -0.698 -0.121 < 0.01
Urinary MAsIII 0.003 -0.031 0.078 0.39 -0.037 -0.608 -0.007 0.02 -0.020 -0.053 0.013 0.25
Urinary DMAsIII 0.023 -0.031 0.078 0.40 -0.404 -0.608 -0.199 < 0.01 -0.301 -0.523 -0.078 < 0.01
Urinary iAsV 0.008 -0.005 0.021 0.23 -0.028 -0.079 0.023 0.29 -0.041 -0.096 0.014 0.14
Urinary MAsV 0.007 -0.086 0.100 0.88 -0.421 -0.777 -0.065 0.02 -0.292 -0.670 0.087 0.13
Urinary DMAsV 0.085 -0.281 0.452 0.65 -1.282 -2.689 0.125 0.07 -0.884 -2.382 0.615 0.25
Urinary DMAs/MAs ratio 0.074 -0.043 0.192 0.22 -0.403 -0.856 0.050 0.08 -0.372 -0.859 0.114 0.13
Urinary
MAs/iAs ratio
0.007 -0.016 0.030 0.56 0.092 0.003 0.182 0.04 0.123 0.030 0.216 0.01
Abbreviations: HbA1c, glycated hemoglobin; FPI, fasting plasma insulin; HOMA-IR, homeostasis model assessment - insulin resistance; b, regression coefficient; CI,
confidence interval.
a Units of b and CI are 10 ppb for iAs concentration. Coefficients for metabolites are standardized to an increment of one inter-quartile range.
b p-value for test of b = 0.
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exposure add to the challenges of determining whether
measurements in drinking water versus urine or current
versus cumulative exposure are the best measure of biolo-
gically-relevant exposure to iAs. Although we were able to
estimate exposure from 1993 onward, 64% of the subjects
had lived in the study area before 1993 and had longer
exposure histories than we could estimate. The sparse
environmental data from the 1980s suggest that iAs levels
in municipal water supplies may have been higher in that
era than in later years. No measurements were available
for years before 1978, but it is possible that iAs exposures
were lower before the construction of municipal water sys-
tems served by deep wells began in the 1960s. In sum-
mary, there are plausible mechanisms for errors resulting
in both under- and over-estimation of cumulative iAs
exposure, but the magnitude and direction of bias in expo-
sure-disease associations as a result of any such errors can-
not be assessed without additional data.
The American Diabetes Association has recommended
that FPG, OGTT or HbA1c be used to test for diabetes
or to assess risk of future diabetes in asymptomatic
patients [37]. However, there is a potential for misclassi-
fication of diabetes status due to error in the field meth-
ods we used to measure these indicators. Any such
error is likely to be random with respect to arsenic
exposure, and so most likely to attenuate associations
between diabetes status and exposure. We also lacked
reliable indicators of social class and were consequently
unable to adjust for it in the analysis. Both Zimapan and
Lagunera are rural, low income areas of Mexico. Recent
data suggest that type-2 diabetes is less prevalent among
Mexican residents with low socioeconomic status [38].
Nevertheless, the potential magnitude of confounding by
social class is difficult to assess, because of the limited
information about the extent to which it is a risk factor
for diabetes in rural Mexican populations.
Finally, the cross-sectional design has well known lim-
itations. In the present study, these relate primarily to the
inability to measure the changes in exposure discussed
above. Because we did not know when the onset of dia-
betes occurred, cumulative exposures may also have been
overestimated for subjects who had the disease for a
number of years. Such overestimation would tend to
understate the association of exposure with disease.
Cross-sectional studies can be susceptible to selection
bias if exposed individuals withdraw from the population
because of exposure or its early effects. However, expo-
sure to iAs in drinking water was not recognized as a
health concern until recently, so it is unlikely to have
prompted more highly exposed individuals to move out
of the study area. In addition, individuals with prevalent
and new-onset diabetes may differ in the way they meta-
bolize arsenic.
Conclusions
Our research links exposure to iAs in drinking water to
an increased risk of developing diabetes which is charac-
terized by fasting hyperglycemia and impaired glucose
tolerance. However, unlike typical type-2 diabetes, iAs-
related diabetes was not associated in this study with
increased insulin resistance as measured by HOMA-IR.
In addition, low FPI levels seem to suggest that b-cell
function may be impaired by exposure to iAs or its
toxic methylated metabolites. In summary, we believe
that strengths of our research outweigh the above-
described limitations, providing additional evidence
about the diabetogenic effects of iAs exposure.
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